Table 3.
The regression probability of MRI in predicting PCa and the thresholds of each group constituted the prostate biopsy rating scale (PBRS).
| Indicators | 0 point | 1 point | 2 points | 3 points |
|---|---|---|---|---|
| Unlikely (normal) | Equivocally | Likely | Highly likely | |
| MP-MRI | ||||
| PI-RADS v2 | 1–2 | 3 | 4 | 5 |
| Regression probability | ≤0.15 | 0.15–0.40 | 0.40–0.65 | >0.65 |
| Thresholds | ||||
| Main indicators | ||||
| PSA (ng/ml) | 0–4 | 4–10 | 10–26 | >26 |
| PSAD (ng/ml2) | ≤0.15 | 0.16–0.20 | 0.20–0.60 | >0.60 |
| PI-RADS (MP-MRI)* | 1–2 | 3 | 4 | 5 |
| Auxiliary indicators | ||||
| Age (year) | <50 | 50–58 | 59–70 | >70 |
| PV (ml) | >454 | 232–454 | 42–232 | <42 |
Notes: 1. Total score (TS): 0–21 points; Negative screening: <12 points, Positive screening: ≥13 points. 2. *This group points are three times that of other groups.
Abbreviations: PSA: prostate-specific antigen; PSAD: PSA density; PV: prostate volume; MP-MRI: multi-parametric magnetic resonance imaging; CI: confidence interval.